Related Experiment Video

Updated: Jun 30, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.2K

Mycophenolate mofetil in autoimmune hepatitis: Are we ready for primetime?

Sagnik Biswas1, Shalimar1

  • 1Department of Gastroenterology and Human Nutrition, All India Institute of Medical Sciences, New Delhi, India.

Journal of Hepatology
|March 22, 2024
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Related Experiment Videos

Last Updated: Jun 30, 2025

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
09:03

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice

Published on: February 3, 2012

19.2K
Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

3.0K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

162
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
162

Articles linked to this work by shared authors, journal, and citation graph.

Predicting Recompensation in Alcohol, HBV and HCV-associated Decompensated Cirrhosis.

Journal of clinical and experimental hepatology·2026

Derivation and internal validation of the enhanced liver fibrosis (ELF)-based prediction score for advanced liver fibrosis in obese patients undergoing bariatric surgery.

Surgical endoscopy·2026

A global consensus on the critical care management of acute-on-chronic liver failure patients: the APASL ACLF Beijing Position Paper.

Hepatology international·2026

Short and long-term outcomes of anorectal biofeedback therapy in patients with functional defecation disorders: Efficacy and predictors of response.

Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology·2026

An Integrated Analysis to Understand the Dysregulation of Innate Immune Response in Mouse Models of MASLD.

Cells·2026

Prior decompensation Identifies Patients at High Mortality Risk Despite Standard Therapy After Variceal Hemorrhage: An IPD Meta-analysis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Corticosteroid Therapy for Drug-induced Liver Injury: Mind the Gap!

Journal of hepatology·2026

Systemic therapy of biliary tract cancer: The road to personalised strategies.

Journal of hepatology·2026

Reproducibility of Biomarkers in MASLD: A Benchmark for Clinically Meaningful Change in Serially Measured Non-Invasive Tests.

Journal of hepatology·2026

The changing epidemiology of primary liver cancer in the 21st century.

Journal of hepatology·2026

Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction.

Journal of hepatology·2026

Non-selective β-blockers reduce bacterial translocation by restoring gut barrier function during experimental cirrhosis.

Journal of hepatology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us